Datasheet

Version: 1.0.0 Revision date: 17 Jul 2024



Sutimlimab

Catalogue No.:abx831466

Sutimlimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting C1S, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Sutimlimab is an anti-C1s antibody. Studies have shown that it can significantly increase hemoglobin levels in patients with primary cold agglutinin disease. Cold agglutinin disease (CAD) is a type of acquired autoimmune hemolytic anemia (AIHA). In cold environments, cold parts of the body will have clinical symptoms related to red blood cell aggregation (for example, the Internet Plaque or cyanosis) and hemolytic anemia.

Target:	C1S
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Isotype:	IgG4 Kappa
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	2049079-64-1
Concentration:	Batch-dependent, typically between 0.5-2.0 mg/ml.

Datasheet

Version: 1.0.0 Revision date: 17 Jul 2024



Note:

This product is for research use only.

Not for human consumption, cosmetic, therapeutic or diagnostic use.



2 of 2

Website: www.abbexa.com · Email: info@abbexa.com